• 4DMedical launches CLEAR, a clinical evidence program to fast-track CT:VQ entry into the PE market
• CLEAR aims to address both nuclear VQ and CTPA-dominated PE opportunities
• The program has the potential to grow the obtainable market for CT:VQ to US$3B

4DMedical Limited, a global leader in respiratory imaging technology, has announced the launch of CLEAR, a clinical evidence program designed to fast-track CT:VQ entry into the acute pulmonary embolism (PE) market. This initiative aims to address both the existing nuclear VQ market and the larger CTPA-dominated PE opportunity, potentially growing the obtainable market for CT:VQ to US$3B. The core study for CLEAR is a multi-centre, multinational, prospective, observational study comparing CT:VQ head-to-head with CTPA in patients with suspected PE. 4DMedical has entered into a clinical research agreement with Mass General Brigham (MGB) affiliated teaching hospitals, with Massachusetts General Hospital serving as the lead site.

Potential market growth for CT:VQ to US$3B

4DMedical aims to improve outcomes for hundreds of thousands of patients by reshaping one of the largest acute CT imaging workflows globally.